secwatch.observer — SEC 8-K summary
======================================

Issuer:     2seventy bio, Inc. (—)
CIK:        0001860782
Form:       8-K
Filed at:   2024-01-30T23:59:59+00:00
Accession:  0001860782-24-000007
Event type: m_and_a
Sentiment:  neutral
Materiality: 0.85
Item codes: 1.01, 2.05, 5.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

2seventy bio sells R&D to Regeneron ($5M), focuses on Abecma; cuts workforce ~14%
--------------------------------------------------------------------------------

- Asset sale to Regeneron for $5M upfront, $10M milestone, royalties; ~160 employees transition; sublease facilities.
- Workforce reduction of ~14%, remaining ~65 employees; one-time restructuring costs ~$8M.
- Expected annual cost savings of ~$150M in 2024 and ~$200M in 2025; cash runway extended beyond 2027.
- CEO Nick Leschly resigns upon closing, becomes Chair; COO Chip Baird named CEO; Victoria Eatwell named CFO.
- Focus exclusively on Abecma with BMS; awaiting ODAC/PDUFA for potential third-line approval in 2024.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1860782/000186078224000007/0001860782-24-000007-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1860782/000186078224000007/tvst-20240128.htm
  HTML page:      https://secwatch.observer/filing/0001860782-24-000007

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer